4//SEC Filing
Smith Brendan 4
Accession 0001209191-21-056064
CIK 0001693415other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 7:33 PM ET
Size
6.2 KB
Accession
0001209191-21-056064
Insider Transaction Report
Form 4
Smith Brendan
Chief Financial Officer
Transactions
- Sale
Stcok Option (right to buy)
2021-09-14−201,800→ 0 totalExercise: $19.23Exp: 2031-04-18→ Common Stock (201,800 underlying)
Footnotes (2)
- [F1]As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
- [F2]This option was granted on April 19, 2021. The shares underlying this option are scheduled to vest over four years, with 25% of the shares vesting on April 19, 2022 and the remainder vesting in equal monthly installments through April 19, 2025.
Documents
Issuer
Translate Bio, Inc.
CIK 0001693415
Entity typeother
Related Parties
1- filerCIK 0001857492
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 7:33 PM ET
- Size
- 6.2 KB